-
Mashup Score: 2
Affinia Therapeutics announced that new preclinical data on its novel AAV capsids for genetic cardiomyopathies and diseases of the central nervous system such as amyotrophic lateral sclerosis, as well as the Company’s high-yield manufacturing process, will be presented in several oral and poster sessions at the American Society of Gene and Cell Therapy 2024 Annual Meeting, being held May 7-11, 2024 in Baltimore, MD and virtually.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 4
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 7AACR 2024: What Cancer Researchers Are Talking About - 17 day(s) ago
The American Association for Cancer Research (AACR)’s annual conference runs April 5 through April 10. BioSpace will have all the key data and news out of San Diego.
Source: www.biospace.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
After BrainStorm Cell Therapeutics withdrew its BLA in October 2023 for NurOwn, the company announced Tuesday that the FDA has agreed to the design of a Phase IIIb trial for its amyotrophic lateral sclerosis candidate under a Special Protocol Assessment.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 1BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS - 18 day(s) ago
BrainStorm Cell Therapeutics Inc. announced that it received written agreement from the U.S. Food and Drug Administration, under a Special Protocol Assessment, on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis.
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 25
Following disappointing Phase III results in less aggressive non-small cell lung cancer, AstraZeneca on Friday announced that Imfinzi improved progression-free and overall survival in patients with limited-stage small cell lung cancer.
Source: www.biospace.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
Months after Johnson & Johnson turned its back on the hypertension treatment Tryvio, Idorsia has secured the FDA’s nod for the endothelin receptor blocker.
Source: www.biospace.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 14Opinion: ALS Is Not a Singular Disease. Stop Treating It Like One - 1 month(s) ago
Imagine testing a really good drug for HER2+ breast cancer in someone with liver cancer. Would it be any surprise when that drug fails?
Source: www.biospace.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 3Merck’s Keytruda Continues NSCLC Losing Streak with Phase III Flop - 1 month(s) ago
Keytruda, when used with AstraZeneca’s Lynparza, did not significantly improve overall and progression-free survival in specific patients with metastatic non-squamous non-small cell lung cancer.
Source: www.biospace.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Cleerly® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System - 2 month(s) ago
Cleerly ® Receives FDA Breakthrough Device Designation for Heart Disease Risk Staging System.
Source: www.biospace.comCategories: General Medicine News, Partners & KOLsTweet
Affinia Therapeutics to Present Data on Novel Cardiotropic and BBB-Penetrant AAV Capsids and Preclinical Efficacy and Safety in Genetic Cardiomyopathies and Sporadic ALS at the American Society of Gene & Cell Therapy 2024 Annual Meeting | BioSpace https://t.co/uuFDqQw6SH #jobs